PUBLICATIONS
20.11
2018
Presentation of the first results of research and development works on V-DOS47 at AACR Annual Meeting 2018 in Chicago.

Dr Anna Bujak presented the first results of Helix Immuno-Oncology at AACR Annual Meeting 2018 in Chicago. We showed the anti-tumor effect of V-DOS47 in the syngeneic mouse model and no such effect in the immunodeficient model. These observations provide the basis for further exploration of the molecule’s mechanism of action and its influence on the immunological system.